Results 11 to 20 of about 193,028 (210)

Complications of bone metastases from malignant melanoma

Journal of Bone Oncology, 2017
Introduction: Metastatic bone disease (MBD) carries significant morbidity for patients with cancer. MBD from malignant melanoma (MM) is understudied. We examined the characteristics, morbidity, management and outcome of MBD in patients with MM.
Jamal Zekri, Maria Marples, Dominic Taylor, Kiran Kandukurti, Lucy McParland, Janet E. Brown   +5 more
doaj   +1 more source

Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland – the SAKK 95/16 prostate study

Swiss Medical Weekly, 2021
BACKGROUND International guidelines state that bone-targeted agents such as denosumab or zoledronic acid at doses used for bone metastasis are not indicated for patients with metastatic castration-sensitive prostate cancer (mCSPC) with bone ...
Sandro T. Stoffel, Roger von Moos, Beat Thürlimann, Richard Cathomas, Silke Gillessen, Ursina Zürrer-Härdi, Thomas von Briel, Sandro Anchisi, Anita Feller, Corinne Schär, Daniel Dietrich, Matthias Schwenkglenks, Judith E. Lupatsch, Michael Mark   +13 more
doaj   +1 more source

Skeletal-Related Events (SRE) in Prostate Cancer: A Report of Two Cases

Folia Medica Indonesiana, 2021
A skeletal-related event (SRE) is an event occurring due to bone metastasis in prostate cancer. SREs are usually marked by pain, pathological fractures, spinal cord compression, hypercalcemia, or bone metastasis requiring radiotherapy or operation.
Anak Agung Ngurah Oka Diatmika, Sunaryo Hardjowijoto   +1 more
doaj   +1 more source

Bone health and therapeutic agents in advanced prostate cancer

Frontiers in Bioscience-Landmark, 2022
Prostate cancer is the most frequent genitourinary tumor worldwide. Maintaining an optimum bone health throughout the natural course of prostate cancer is an important aspect in the management of this disease, particularly in this at risk population of ...
Maria Antonia Gómez-Aparicio, Fernando López-Campos, Lira Pelari-Mici, David Buchser, Jorge Pastor, Xavier Maldonado, Juan Zafra, Alison C. Tree, Renée Bultijnck, Paul Sargos, Piet Ost, Felipe Couñago   +11 more
doaj   +1 more source

Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis

Cancer Medicine, 2016
The purpose of this study was to estimate the risk of developing skeletal‐related events (SREs) based on site of metastasis at diagnosis and identify other predictors of developing SREs among metastatic prostate cancer patients.
Arif Hussain, Abdalla Aly, C. Daniel Mullins, Yi Qian, Jorge Arellano, Eberechukwu Onukwugha   +5 more
doaj   +1 more source

Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot study

Bone Reports
Background: Patients with bone metastases from solid tumors often have additional treatment with bone targeted agents (BTAs) to avoid symptomatic skeletal events (SSEs) such as clinically significant pathological fracture leading toradiation therapy or ...
Michael Mark, Alfonso Rojas Mora, Thomas Winder, Anastasios Stathis, Andreas Jakob, Gisela Müller, Stefanie Hayoz, Patrick Reimann, Ulf Petrausch, Roger von Moos   +9 more
doaj   +1 more source

The effects of daratumumab on bone disease in patients with newly diagnosed multiple myeloma: a multi-center retrospective study

BMC Cancer
Background Daratumumab (Dara), a humanized IgGκ monoclonal antibody targeting CD38, has shown significant efficacy in the treatment of multiple myeloma (MM).
Xinrong Li, Hua Wang, Yizhen Li, Jing Zhou, Nianhui Yang, Xiaolei Wei, Xiangran Cai, Zeyu Xiao, Juan Du, Hui Zeng   +9 more
doaj   +1 more source

Managing Bone Metastases with Denosumab: Real-World Data and Critical Monitoring Points in Breast, Lung, and Prostate Cancers

Medicina
Background and Objectives: Advanced solid organ tumors, particularly breast, lung, and prostate cancers, frequently metastasize to bone, leading to debilitating skeletal-related events (SREs).
Sibel Oyucu Orhan, Bedrettin Orhan, Şeyma Esenbuğa, Seda Sali, Burcu Caner, Birol Ocak, Ahmet Bilgehan Şahin, Adem Deligönül, Türkkan Evrensel, Erdem Çubukçu   +9 more
doaj   +1 more source

Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials

Frontiers in Oncology, 2023
Denosumab, a fully humanized monoclonal neutralizing antibody, inhibits activation of the RANK/RANKL/OPG signaling pathway through competitive binding with RANKL, thereby inhibiting osteoclast-mediated bone resorption.
Junjie Lu, Desheng Hu, Yan Zhang, Chen Ma, Lin Shen, Bo Shuai   +5 more
doaj   +1 more source

Impact of Initial Treatment Setting on Survival in Relapsed Pediatric and AYA Bone Sarcomas: A Secondary Analysis of a Prospective Clinical Trial

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Outcomes in relapsed or refractory pediatric and AYA bone sarcomas remain poor, and the impact of early referral to specialized sarcoma centers on survival is unclear. Early centralization of care may improve local and systemic treatment quality, but evidence in this population is limited.
Justyna Antoniuk‐Majchrzak, Katarzyna Bilska, Tomasz Koziński, Jadwiga Węcławek‐Tompol, Dorota Sega‐Pondel, Radosław Chaber, Wanda Badowska, Katarzyna Rosłan, Hanna Koseła‐Paterczyk, Anna Raciborska   +9 more
wiley   +1 more source